Genmab — Oktober 2014
-
Presenting the new analysis at the American Academy of Neurology (AAN) 66th Annual Meeting, Daren Austin, PhD, from GSK UK, explained that the study included a large range of doses in an attempt to pinpoint the lowest dose for significantly reducing MRI lesion activity.
-
For the MIRROR study, 231 patients with relapsing-remitting MS were randomly assigned to 1 of 4 doses of ofatumumab or placebo. The 4 doses were 3 mg every 12 weeks, 30 mg every 12 weeks, 60 mg every 12 weeks, and 60 mg every 4 weeks. After 12 weeks, the placebo group received 3 mg of ofatumumab. The study treatments were given for 24 weeks. The primary endpoint was suppression of MRI lesion activity during the first 12 weeks.
Results suggested a 90% or greater reduction in the cumulative numbe
-
-
-
Safety fra MIRROR...There were no unexpected safety findings in the study, the company reports. Between weeks 0 and 12, injection-related reactions were the most common adverse reaction, seen in 52% of patients receiving ofatumumab vs 15% of those receiving placebo. Five serious adverse events were reported, all in patients receiving the 60-mg dose, but none of these patients withdrew from the study.
-
Som US ser ud lige nu får den nok tæsk tæsk tæsk imorgen
-
det lignede et sammenbrud i luk
-
JSEH man skal ALDRIG være nervøs når en kurs falder uden grund er min klare overbevisning. Og slet ikke når en aktie som er steget fra 15 til 44 i år falder tilbage til 36... Så jeg afventer bare Q3 regnskabet og supplerer eventuelt ved flere tilbagefald
-
Ser ud til åbning helt nede omkring 245
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind